The first targeted therapy for MASLD, a selective thyroid hormone receptor- agonist called resmetirom, was approved by the U.S
Always consult a qualified healthcare professional before starting any peptide protocol
El Asmar assesses your overall health, weight history, metabolism, lifestyle, and goals to determine whether tirzepatide is appropriate for you
Because theyre worried about potentially having to stop the medication or theyre embarrassed to bring up diarrhea, constipation, and other GI troubles
Feeling faint or as if the room is spinning
A key advantage of retatrutide is the high percentage of weight loss achieved in a significantly shorter study duration of 24 weeks, compared to the 68 weeks in the STEP 2 trial for semaglutide 35 and 72 weeks in the SURMOUNT trial for tirzepatide